Does DARBEPOETIN ALFA Cause Second primary malignancy? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Second primary malignancy have been filed in association with DARBEPOETIN ALFA (ARANESP). This represents 0.0% of all adverse event reports for DARBEPOETIN ALFA.
5
Reports of Second primary malignancy with DARBEPOETIN ALFA
0.0%
of all DARBEPOETIN ALFA reports
1
Deaths
1
Hospitalizations
How Dangerous Is Second primary malignancy From DARBEPOETIN ALFA?
Of the 5 reports, 1 (20.0%) resulted in death, 1 (20.0%) required hospitalization.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DARBEPOETIN ALFA. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does DARBEPOETIN ALFA Cause?
Death (12,264)
Hospitalisation (5,682)
Product storage error (1,619)
Off label use (1,586)
Circumstance or information capable of leading to medication error (1,050)
Haemodialysis (907)
Pneumonia (733)
Fall (726)
Anaemia (562)
Dialysis (555)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which DARBEPOETIN ALFA Alternatives Have Lower Second primary malignancy Risk?
DARBEPOETIN ALFA vs DARIDOREXANT
DARBEPOETIN ALFA vs DARIFENACIN HYDROBROMIDE
DARBEPOETIN ALFA vs DAROLUTAMIDE
DARBEPOETIN ALFA vs DARUNAVIR
DARBEPOETIN ALFA vs DARUNAVIR ETHANOLATE